Introduction: Congenital afibrinogenemia is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Hypofibrinogenemia is characterized by fibrinogen levels <1.5 g/L. Objective: In this study, we analyzed fibrinogen beta chain gene mutations in Turkish afibrinogenemia and hypofibrinogenemia patients. Methods: We evaluated 20 afibrinogenemia and hypofibrinogenemia patients and 80 healthy controls. We have sequenced all exons of the FGB gene using the DNA isolated from the peripheral blood samples of patients and controls. Results and Conclusion: We found a nonsense mutation in exon 4 at nucleotide 630 that encoded serine amino acid, and in the same exon a missense mutation of T to C at nucleotide 647, resulting in a transition from leucine to proline (p.L198P) in a child with hypofibrinogenemia. These mutations have been shown for the first time in the same patient of Turkish descent. Furthermore, there was a novel heterozygous guanine-to-adenine nucleotide change in exon 3. This caused the change of arginine amino acid to threonine amino acid at position 136 (p.A136T) in a protein, which has not been described in the literature before.

1.
Asselta
R
,
Duga
S
,
Tenchini
ML
.
The molecular basis of quantitative fibrinogen disorders
.
J Thromb Haemost
.
2006
Oct
;
4
(
10
):
2115
29
.
[PubMed]
1538-7933
2.
Moerloose
P
,
Boehlen
F
,
Neerman-Arbez
M
.
Fibrinogen and the risk of thrombosis
.
Volume 36
.
Thromb Hemost
;
2010
.
3.
Doolittle
RF
.
Fibrinogen and fibrin
.
Annu Rev Biochem
.
1984
;
53
(
1
):
195
229
.
[PubMed]
0066-4154
4.
Peyvandi
F
,
Duga
S
,
Akhavan
S
,
Mannucci
PM
.
Rare coagulation deficiencies
.
Haemophilia
.
2002
May
;
8
(
3
):
308
21
.
[PubMed]
1351-8216
5.
de Moerloose
P
,
Neerman-Arbez
M
.
Congenital fibrinogen disorders
.
Semin Thromb Hemost
.
2009
Jun
;
35
(
4
):
356
66
.
[PubMed]
0094-6176
6.
Neerman-Arbez
M
,
de Moerloose
P
.
Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations
.
Hum Mutat
.
2007
Jun
;
28
(
6
):
540
53
.
[PubMed]
1059-7794
7.
Casini
A
,
Vilar
R
,
Beauverd
Y
,
Aslan
D
,
Devreese
K
,
Mondelaers
V
, et al.
Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia
.
Haemophilia
.
2017
Jul
;
23
(
4
):
583
9
.
[PubMed]
1351-8216
8.
Duga
S
,
Asselta
R
,
Santagostino
E
,
Zeinali
S
,
Simonic
T
,
Malcovati
M
, et al.
Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion
.
Blood
.
2000
Feb
;
95
(
4
):
1336
41
.
[PubMed]
0006-4971
9.
Maghzal
GJ
,
Brennan
SO
,
Homer
VM
,
George
PM
.
The molecular mechanisms of congenital hypofibrinogenaemia
.
Cell Mol Life Sci
.
2004
Jun
;
61
(
12
):
1427
38
.
[PubMed]
1420-682X
10.
Taira
C
,
Matsuda
K
,
Arai
S
,
Sugano
M
,
Uehara
T
,
Okumura
N
.
A Novel Mutation in the Fibrinogen Bβ Chain (c.490G[{GT}]A; End of Exon 3) Causes a Splicing Abnormality and Ultimately Leads to Congenital Hypofibrinogenemia
.
Int J Mol Sci
.
2017
Nov
;
18
(
11
):
E2470
.
[PubMed]
1661-6596
11.
Koenig
W
.
Fibrin(ogen) in cardiovascular disease: an update
.
Thromb Haemost
.
2003
Apr
;
89
(
4
):
601
9
.
[PubMed]
0340-6245
12.
Fışgın
T
,
Balkan
C
,
Celkan
T
,
Kılınç
Y
,
Türker
M
,
Timur
C
, et al.
Rare coagulation disorders: a retrospective analysis of 156 patients in Turkey
.
Turk J Haematol
.
2012
Mar
;
29
(
1
):
48
54
.
[PubMed]
1300-7777
13.
Patiroglu
T
,
Karakukcu
M
.
Middle cerebral arterial thrombosis in a patient with hypofibrinogenemia, 5 days after rFVIIa and FFP infusion
.
Clin Appl Thromb Hemost
.
2006
Jan
;
12
(
1
):
111
3
.
[PubMed]
1076-0296
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.